Vulnerability in Pharmaguideline
CVE-2014-6721
The Pharmaguideline (aka com.pharmaguideline) application 1.2.0 for Android does not verify X.509 certificates from SSL servers, which allows man-in-the-middle attackers to spoof servers and obtain sensitive information via a crafted certificate.
Vulnerability class: POODLE (CVE-2014-3566)
Published · last modified .
CVSS v2 metric
CVSS v2 base score 5.4 (Medium). Vector: AV:A/AC:M/Au:N/C:P/I:P/A:P. This CVE predates CVSS v3 and has no v3 score from NVD.
EPSS exploit prediction
EPSS: 0.007 (49.6th percentile), scored .
Very low probability of exploitation in the next 30 days; routine patching cadence is appropriate. 50th percentile — 49.6% of CVEs in the catalogue have a lower EPSS than this one. How to read EPSS.
EPSS over last 30 days · oldest: 0.007 · newest: 0.007 · change: 0.000
Affected products
- Pharmaguideline — versions 1.2.0
Weakness classification (CWE)
Public proof-of-concept exploits
References
- www.kb.cert.org/vuls/id/819305 (US Government Resource, third-party-advisory)
- www.kb.cert.org/vuls/id/582497 (US Government Resource, third-party-advisory)
- docs.google.com/spreadsheets/d/1t5GXwjw82SyunALVJb2w0zi3FoLRIkfGPc7AMjRF0r4/edit
Frequently asked questions
- What is CVE-2014-6721?
- CVE-2014-6721 is a vulnerability in Pharmaguideline, classified under Cryptographic Issues. Published 2014-09-26.
- Is CVE-2014-6721 known to be exploited?
- 2 public proof-of-concept repositories are indexed. Not currently listed in the CISA KEV catalog.